Professor David Castle, Chair Psychiatry St Vincent’s Hospital and University of Melbourne and Board Director Mind Medicine Australia, answers some of the big questions about the re-emerging field of psychedelic-assisted psychotherapy in this Q&A.
Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The Australian Drug Harms Ranking Study. J Psychopharmacol. 2019 Jul; 33(7): 759-68. DOI: 10.1177/0269881119841569
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res 2020 Feb; 284: 112749. DOI: 10.1016/j.psychres.2020.112749
Meikle SE, Liknaitzky P, Rossell SL, Ross M, Strauss N, Thomas N, et al. Psilocybin-assisted therapy for depression: how do we advance the field? Aust N Z J Psychiatry. 2020 Mar; 54(3): 225-31. DOI: 10.1177/0004867419888575
Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomised controlled trials. Psychopharmacology (Berl). 2019 Sep: 236(9): 2735-45. DOI: 10.1007/s00213-019-05249-5
Listen to expert interviews.
Click to open in a new tab
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
